MedPath

ImmunityBio Initiates Phase 1 Trial of CD19 t-haNK Cell Therapy for Non-Hodgkin Lymphoma

• ImmunityBio's stock surged following the launch of a Phase 1 trial (QUILT 106) in South Africa for CD19 t-haNK cell therapy targeting non-Hodgkin lymphoma. • The trial will evaluate the novel therapy as a standalone treatment and in combination with rituximab, aiming to enroll up to 100 patients by early 2025. • This initiative reflects ImmunityBio's strategy to use CAR-NK technology to address unmet needs in liquid tumors, with initial data expected by the second half of 2025. • The study emphasizes addressing unmet medical needs in Sub-Saharan Africa, potentially establishing a benchmark for future research in underserved regions.

ImmunityBio has initiated a Phase 1 clinical trial (QUILT 106) in South Africa to evaluate its CD19-targeted t-haNK cell therapy for the treatment of non-Hodgkin lymphoma. The trial represents ImmunityBio's first natural killer cell-based trial in the region.
The QUILT 106 study aims to enroll up to 100 patients by early 2025 and will assess the safety and efficacy of the CD19 t-haNK cell therapy both as a monotherapy and in combination with rituximab. This approach seeks to address gaps where existing therapies have limitations, particularly in liquid tumors.
Patrick Soon-Shiong, executive chairman of ImmunityBio, highlighted the significance of the trial in addressing unmet medical needs in Sub-Saharan Africa. The trial could potentially set a precedent for future research and treatment accessibility in underserved areas.
By leveraging CAR-NK technology, ImmunityBio aims to generate critical data by the second half of 2025 that could reshape how non-Hodgkin lymphoma is treated. The company is positioning itself as a disruptor in the cancer therapy space.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Nuvalent's Lung Cancer Drug Shows Promise Amid Risks

Nuvalent, Inc., a clinical-stage biotechnology company, is making significant strides in the development of brain-penetrant tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC). With promising early-stage clinical trial results for its lead candidates, zidesamtinib and NVL-655, and a strong financial foundation, Nuvalent is poised for potential commercialization. However, the company faces challenges in a competitive NSCLC treatment market and risks associated with clinical trial setbacks.

Artiva Biotherapeutics' NK Cell Therapy Shows Promise for Autoimmune Disease Treatment

Artiva Biotherapeutics is developing unengineered NK cell therapies for autoimmune diseases, potentially offering durable, drug-free remissions.
The company's lead candidate, AB-101, targets lupus and lupus nephritis, with initial clinical data expected in the first half of 2025.

HanX Biopharmaceuticals Eyes Hong Kong IPO to Advance Bispecific Antibody HX009

HanX Biopharmaceuticals is planning an IPO in Hong Kong to fund clinical trials for its lead drug candidate, HX009, a bispecific antibody targeting PD-1 and CD47.
HX009 is currently in early-phase studies for advanced melanoma and Epstein-Barr virus-linked lymphomas, with a phase 2 trial planned for biliary tract cancer.

HOOKIPA Pharma's HB-200 Shows Promise in HPV16+ Head and Neck Cancer Treatment

HOOKIPA Pharma's HB-200 (eseba-vec) demonstrates encouraging results in clinical trials for HPV16-positive head and neck cancers, addressing a significant unmet medical need.
A pivotal Phase 2/3 trial (AVALON-1) is slated to begin in Q4 2024, evaluating HB-200 in combination with Keytruda for first-line treatment, with initial results expected in 2026.

Imugene's VAXINIA Shows Sustained Complete Response in Bile Tract Cancer Patient

Imugene's VAXINIA (CF33-hNIS) demonstrates a complete response in a bile tract cancer patient for over two years in the Phase 1 MAST trial, highlighting its potential efficacy.
The Bile Tract Cancer Expansion part of the MAST trial has cleared its first cohort with no dose-limiting toxicities, allowing for full enrollment of up to 10 patients.

Biofrontera's Ameluz Demonstrates High Efficacy in Phase III sBCC Trial

Biofrontera's Ameluz-PDT therapy met the primary endpoint, showing 65.5% success in complete clearance of superficial basal cell carcinoma (sBCC) lesions, compared to 4.8% with placebo.
The Phase III trial demonstrated that 75.9% of participants treated with Ameluz-PDT achieved complete histological clearance, versus 19% in the placebo group.

MB-105, a CD5-Targeted CAR-T Cell Therapy, Receives FDA Orphan Drug Designation for T-Cell Lymphoma

March Biosciences' MB-105, a first-in-class CD5 CAR-T cell therapy, has received FDA Orphan Drug Designation for relapsed/refractory CD5-positive T-cell lymphoma.
The Orphan Drug Designation provides incentives including tax credits, user fee exemptions, and seven years of market exclusivity post-approval.

ImmunityBio Initiates Phase I Trial of CD19-Targeted haNK Cell Therapy for NHL in South Africa

ImmunityBio has commenced a Phase I clinical trial in South Africa evaluating its CD19-targeted high-affinity natural killer (t-haNK) cell therapy for non-Hodgkin’s lymphoma (NHL).
The QUILT 106 trial will assess the safety and preliminary efficacy of CD19 t-haNK cells, both as a single agent and in combination with rituximab, a standard NHL treatment.

ImmunityBio Launches Phase 1 Trial of CD19 t-haNK Cell Therapy for Non-Hodgkin Lymphoma

ImmunityBio initiated a Phase 1 trial (QUILT 106) in South Africa to evaluate CD19 t-haNK cell therapy for non-Hodgkin lymphoma.
The trial will enroll up to 100 patients by early 2025, testing the therapy alone and in combination with rituximab.

Bicara, Zenas, and MBX Bio Launch IPOs, Raising $703M for Clinical Trials

Bicara Therapeutics raised $315 million to fund a pivotal trial of ficerafusp alfa for head and neck squamous cell carcinoma (HNSCC).
Zenas Biopharma secured $225 million to advance obexelimab, a bifunctional antibody, through Phase 3 trials for IgG4-related disease and Phase 2 trials for multiple sclerosis, lupus, and wAIHA.

Reference News

[1]
ImmunityBio Soars 56% in a Day: Is This Cancer Breakthrough the Next $30 Stock?
gurufocus.com · Oct 26, 2024

ImmunityBio's stock surged 56% to $6.57 on the launch of its Phase 1 trial for CD19 t-haNK cell therapy in South Africa,...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy